MissionIR Articles

Cardium Therapeutics is a health sciences and regenerative medicine company strategizing to acquire and develop new and innovative bio-medical product opportunities that have definable pathways to commercialization, partnering, sale, or other economic monetizations. To avoid…

Asset-based health sciences and regenerative medicine company Cardium Therapeutics operates under a business model that involves creating multiple success opportunities without relying on any one technology platform or product type. Focused on acquiring and strategically…

Cardium Therapeutics is an asset-based health sciences and regenerative medicine company that focuses on new and innovative bio-medical product opportunities and businesses that have potential to address significant unmet medical needs. The company seeks to…

Cardium Therapeutics has developed a unique portfolio of businesses and product opportunities in the fields of health sciences and regenerative medicine. Among other opportunities in its portfolio, the company’s lead clinical development product candidate, Generx®,…

As an asset-based health sciences and regenerative medicine company, Cardium Therapeutics focuses on acquiring and developing innovative products and businesses that have the potential to fulfill significant unmet medical needs. In its quest to develop…

Cardium Therapeutics is a health sciences and regenerative medicine company building a portfolio of bio-medical opportunities and businesses with a definable pathway to commercialization and the potential to revolutionize the healthcare industry by meeting unmet…

Asset-based health sciences and regenerative medicine company Cardium Therapeutics is focused on acquiring and strategically developing new and innovative biomedical product opportunities and businesses. The company acquires and develops opportunities and businesses that have the…

Cardium Therapeutics is engaged in the acquisition and development of innovative products that fall within a set range of criterion, focused on products and businesses that have demonstrated their potential to address significant unmet medical…

LifeAgain Insurance Solutions, a wholly owned subsidiary of Cardium Therapeutics, today announced its support of Life Insurance Awareness Month. Taking place during September, this campaign is sponsored by the Life and Health Insurance Foundation for…

Cardium Therapeutics just announced that LifeAgain™ Insurance Solutions Inc., a wholly-owned subsidiary, and AgencyONE, its commercialization partner, have entered into agreements to market and sell term life insurance issued by Symetra Life Insurance Company under…

New analytical tools and technologies have become a major part of modern medicine, saving lives through a combination of early problem detection and a growing understanding of how the human body operates. Advanced genetics is…

Cardiovascular disease is responsible for 17 million deaths around the globe, making it the No. 1 cause of death worldwide, according to the American Heart Association and the World Health Organization. The disease is often…

Cardium Therapeutics recently announced that its wholly-owned subsidiary, LifeAgain™ Insurance Solutions Inc., has entered into a commercialization agreement with AgencyONE. The agreement will have LifeAgain™ supporting the development and commercialization of innovative, survivable risk life…

Cardium Therapeutics today presented recent highlights and other business developments while reporting its financial results for the second quarter ended June 30, 2013. The company said it now has four business units in its portfolio:…

Cardium Therapeutics, a health sciences and regenerative medicine company, today announced its research collaboration with researchers at Boston Children’s Hospital to assess the medical utility of Cardium’s Excellagen® to repair prenatally diagnosed birth defects using…

Today before the opening bell, Cardium Therapeutics announced that it has entered into a distribution agreement with Kasiak Holdings AG for the marketing and sale of Excellagen® advanced wound care product in Germany and Switzerland.…

Cardium Therapeutics, an asset-based health sciences and regenerative medicine company, has signed an agreement with Orbsen Therapeutics Ltd. and the National University of Ireland, Galway, to utilize Cardium’s FDA-cleared Excellagen® gel as a delivery agent…

Earlier today Cardium Therapeutics, an asset-based, health sciences and regenerative medicine company, announced the filing of a new 510(k) submission for its current FDA-cleared Excellagen® advanced wound care product. The filing reflects additional and specific…

Today before the open, Cardium Therapeutics announced that it has signed a distribution agreement with AvKARE encompassing government medical facilities throughout the United States. The new commercialization arrangement with AvKARE effectively replaces an earlier arrangement…

The financial front has been especially active for Cardium Therapeutics over the past few weeks. The San Diego based health sciences and regenerative medicine company finalized and executed a reverse stock split, a condition of…